Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
Immune checkpoint inhibitors are increasingly used in combination with chemotherapy for the treatment of non-small cell lung cancer, yet the success of combination therapies is relatively limited. Thus, more detailed insight regarding the tumor molecular markers that may affect the responsiveness of...
Saved in:
Main Authors: | Marika Saar (Author), Jana Jaal (Author), Alvin Meltsov (Author), Tõnis Laasfeld (Author), Helen Lust (Author), Sergo Kasvandik (Author), Darja Lavogina (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
by: Zhuo-miao Ye, et al.
Published: (2023) -
First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Wenjie Liu, et al.
Published: (2023) -
Durvalumab-associated generalized morphea with overlapping vitiligo
by: Julianna Martel, MD, et al.
Published: (2022) -
Skin puckering and edema during durvalumab therapy
by: Brianna Olamiju, BA, et al.
Published: (2021) -
Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment
by: Yudai Fujiwara, et al.
Published: (2024)